Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Loa Loa (eye worm) | transcription factor SMAD2 | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Loa Loa (eye worm) | MH2 domain-containing protein | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Brugia malayi | MH2 domain containing protein | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.0114 | 0.7704 | 1 | |
Loa Loa (eye worm) | FAT-3 protein | 0.0113 | 0.7677 | 0.7677 |
Echinococcus multilocularis | Peptidase M, neutral zinc metallopeptidases, zinc binding site | 0.0011 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable conserved membrane protein | 0.0012 | 0.0027 | 1 |
Echinococcus multilocularis | Fatty acid desaturase, type 1 | 0.0011 | 0 | 0.5 |
Echinococcus multilocularis | Peptidase M, neutral zinc metallopeptidases, zinc binding site | 0.0011 | 0 | 0.5 |
Brugia malayi | Delta5 fatty acid desaturase | 0.0113 | 0.7677 | 0.7677 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 1 | 1 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 1 | 1 |
Echinococcus granulosus | Sphingolipid delta4 desaturase DES1 | 0.0011 | 0 | 0.5 |
Trypanosoma cruzi | delta-4 fatty acid desaturase, putative | 0.0012 | 0.0027 | 1 |
Trypanosoma cruzi | delta-4 fatty acid desaturase, putative | 0.0012 | 0.0027 | 1 |
Leishmania major | stearic acid desaturase, putative | 0.0012 | 0.0027 | 0.0035 |
Leishmania major | delta-5 fatty acid desaturase | 0.0113 | 0.7677 | 1 |
Trypanosoma cruzi | fatty acid desaturase, putative | 0.0012 | 0.0027 | 1 |
Trypanosoma brucei | fatty acid desaturase, putative | 0.0012 | 0.0027 | 1 |
Leishmania major | fatty-acid desaturase, putative | 0.0012 | 0.0027 | 0.0035 |
Loa Loa (eye worm) | hypothetical protein | 0.0102 | 0.6824 | 0.6824 |
Mycobacterium ulcerans | hypothetical protein | 0.0012 | 0.0027 | 1 |
Toxoplasma gondii | sphingolipid delta 4 desaturase/c-4 hydroxylase protein des2 family protein | 0.0011 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0113 | 0.7677 | 0.7677 |
Leishmania major | delta-6 fatty acid desaturase | 0.0012 | 0.0027 | 0.0035 |
Echinococcus granulosus | Fatty acid desaturase type 1 | 0.0011 | 0 | 0.5 |
Schistosoma mansoni | fatty acid desaturase | 0.0114 | 0.7704 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.1122 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 0.3981 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 32.6427 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.